Jesse Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jesse Qiao has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Gagan Mathur
Department of Pathology and Laboratory Medicine University of California, Irvine Orange California USA
5 shared publications- Jude Abadie
Department of Pathology at Texas Tech Health Sciences Center, El Paso, TX, USA
3 shared publications Laura Rabichow
Hematology Laboratory, University of California (UCI) Health, Orange, USA
2 shared publicationsLila Nguyen
Hematology Laboratory, University of California (UCI) Health, Orange, USA
2 shared publicationsMinh-Ha Tran
University of California, Irvine, Department of Pathology & Laboratory Medicine, Orange, CA, United States
2 shared publicationsMinh‐Ha Tran
Department of Pathology & Laboratory Medicine University of California, Irvine Orange California USA
2 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (2) , 293-295
Continuity of care in immune thrombotic thrombocytopenic purpura ( iTTP ): A visual roadmap for survivorship beyond acute management
- 8 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (2) , 293-295
Open AccessContinuity of care in immune thrombotic thrombocytopenic purpura ( iTTP ): A visual roadmap for survivorship beyond acute management
- Open Access
- 15 October 2025
- Published by Wiley in Vox Sanguinis
- Vol. 121 (1) , 35-42
Exploring low haemoglobin density as a no‐added‐cost screening marker to assess iron deficiency
Background and Objectives: Iron deficiency (ID), with or without anaemia, affects over 1 billion people globally. Early detection is essential, but current diagnostic tools may be costly, logistically complex and not widely accessible. This study evaluates low haemoglobin density percentage (LHD%), derived from mean corpuscular haemoglobin concentration (MCHC) in routine complete blood counts (CBCs), as a no‐added‐cost, accessible alternative for ID screening. Materials and Methods: We retrospectively analysed 3526 adult patient records (January–April 2025) from a single‐centre institution, including those with iron panel and CBC performed within 24 h. Patients were categorized as Normal, ID, ID anaemia (IDA) or anaemia without ID (AwoID). LHD% was calculated and assessed across groups using receiver operating characteristic (ROC) curve analyses for cutoff determinations. Results: Median LHD% increased progressively from the Normal group (2.99%) to the IDA group (6.71%). ROC analysis showed modest but acceptable diagnostic performance: area under the curve (AUC) was 0.677 overall, 0.687 in non‐anaemic and 0.684 in anaemic subjects. Specific LHD% cutoffs varied by context: >4.48% for general screening (61% sensitivity, 67% specificity), >7.02% for donor screening (95% specificity) and >3.74% for anaemia workup (75% sensitivity). Conclusion: LHD% shows potential as a context‐specific, no‐added‐cost screening tool for ID using existing CBC data. While its diagnostic performance is modest, its scalability and accessibility could support broader public health screening efforts. Further prospective validation is recommended.
- 15 October 2025
- Published by Wiley in Vox Sanguinis
- Vol. 121 (1) , 35-42
Open AccessExploring low haemoglobin density as a no‐added‐cost screening marker to assess iron deficiency
Background and Objectives: Iron deficiency (ID), with or without anaemia, affects over 1 billion people globally. Early detection is essential, but current diagnostic tools may be costly, logistically complex and not widely accessible. This study evaluates low haemoglobin density percentage (LHD%), derived from mean corpuscular haemoglobin concentration (MCHC) in routine complete blood counts (CBCs), as a no‐added‐cost, accessible alternative for ID screening. Materials and Methods: We retrospectively analysed 3526 adult patient records (January–April 2025) from a single‐centre institution, including those with iron panel and CBC performed within 24 h. Patients were categorized as Normal, ID, ID anaemia (IDA) or anaemia without ID (AwoID). LHD% was calculated and assessed across groups using receiver operating characteristic (ROC) curve analyses for cutoff determinations. Results: Median LHD% increased progressively from the Normal group (2.99%) to the IDA group (6.71%). ROC analysis showed modest but acceptable diagnostic performance: area under the curve (AUC) was 0.677 overall, 0.687 in non‐anaemic and 0.684 in anaemic subjects. Specific LHD% cutoffs varied by context: >4.48% for general screening (61% sensitivity, 67% specificity), >7.02% for donor screening (95% specificity) and >3.74% for anaemia workup (75% sensitivity). Conclusion: LHD% shows potential as a context‐specific, no‐added‐cost screening tool for ID using existing CBC data. While its diagnostic performance is modest, its scalability and accessibility could support broader public health screening efforts. Further prospective validation is recommended.
- 2 October 2025
- Published by Wiley in Transfusion
- Vol. 65 (11) , 2178-2191
Revisiting a “new” yet “old” approach: Reticulocyte hemoglobin and related hematological indices for iron deficiency screening for patient blood management
- 2 October 2025
- Published by Wiley in Transfusion
- Vol. 65 (11) , 2178-2191
Revisiting a “new” yet “old” approach: Reticulocyte hemoglobin and related hematological indices for iron deficiency screening for patient blood management
- 3 August 2025
- Published by Wiley in Transfusion
Modernizing iron screening: The case for reticulocyte hemoglobin
- 3 August 2025
- Published by Wiley in Transfusion
Modernizing iron screening: The case for reticulocyte hemoglobin
- Open Access
- 26 July 2025
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 56 (6) , 813-818
Prolonged COVID-19 infection in a patient with B-cell acute lymphoblastic leukemia maintained on convalescent plasma until recovery with monoclonal antibodies
Introduction: Patients with hematologic malignancies who undergo immunosuppressive therapies such as chimeric antigen receptor T-cell (CAR-T) therapy are at high risk of prolonged SARS-CoV-2 infection due to impaired humoral immunity. Treatment options remain limited, with variable efficacy, in such settings. Methods: We describe a 21-year-old man with Down syndrome and B-cell acute lymphoblastic leukemia complicated by B-cell aplasia following CD19-directed CAR-T therapy. The patient developed COVID-19 and experienced persistent symptomatic infection, with high viral load and prolonged reverse transcriptase–polymerase chain reaction (RT-PCR) positivity for more than 7 months. Results: Despite multiple courses of remdesivir and extended weekly infusions of COVID-19 convalescent plasma (CCP), the patient remained viremic and intermittently symptomatic. Anti–SARS-CoV-2 immunoglobulin G titers were detectable only toward the latter time frame of treatment, and passive antibody therapy with CCP was insufficient for viral clearance. Ultimately, compassionate use of monoclonal antibody (mAb) therapy (casirivimab and imdevimab) was granted. Following administration, the patient achieved viral clearance for the first time, with resolution of symptoms and persistently negative RT-PCR findings for 8 months of available follow-up thereafter. Discussion: This case illustrates the limitations of CCP in patients with prolonged SARS-CoV-2 infection and highlights the effectiveness of mAbs in achieving viral clearance in severely immunocompromised hosts. It supports targeted use of mAb therapy in select high-risk populations and reinforces the importance of specific passive immunotherapy strategies (when available) for the management of viremia in immunodeficient patients.
- 26 July 2025
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 56 (6) , 813-818
Open AccessProlonged COVID-19 infection in a patient with B-cell acute lymphoblastic leukemia maintained on convalescent plasma until recovery with monoclonal antibodies
Introduction: Patients with hematologic malignancies who undergo immunosuppressive therapies such as chimeric antigen receptor T-cell (CAR-T) therapy are at high risk of prolonged SARS-CoV-2 infection due to impaired humoral immunity. Treatment options remain limited, with variable efficacy, in such settings. Methods: We describe a 21-year-old man with Down syndrome and B-cell acute lymphoblastic leukemia complicated by B-cell aplasia following CD19-directed CAR-T therapy. The patient developed COVID-19 and experienced persistent symptomatic infection, with high viral load and prolonged reverse transcriptase–polymerase chain reaction (RT-PCR) positivity for more than 7 months. Results: Despite multiple courses of remdesivir and extended weekly infusions of COVID-19 convalescent plasma (CCP), the patient remained viremic and intermittently symptomatic. Anti–SARS-CoV-2 immunoglobulin G titers were detectable only toward the latter time frame of treatment, and passive antibody therapy with CCP was insufficient for viral clearance. Ultimately, compassionate use of monoclonal antibody (mAb) therapy (casirivimab and imdevimab) was granted. Following administration, the patient achieved viral clearance for the first time, with resolution of symptoms and persistently negative RT-PCR findings for 8 months of available follow-up thereafter. Discussion: This case illustrates the limitations of CCP in patients with prolonged SARS-CoV-2 infection and highlights the effectiveness of mAbs in achieving viral clearance in severely immunocompromised hosts. It supports targeted use of mAb therapy in select high-risk populations and reinforces the importance of specific passive immunotherapy strategies (when available) for the management of viremia in immunodeficient patients.
- Open Access
- 7 June 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (4) , 104174
Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura
- 7 June 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (4) , 104174
Open AccessRelapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura
- 16 May 2025
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 141 (5) , 1181-1184
The Effect of Acute Normovolemic Hemodilution on Coagulation During Cardiac Surgery Using Sonorheometric Clot Analysis (Quantra QPlus): A Retrospective Pilot Study
- 16 May 2025
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 141 (5) , 1181-1184
The Effect of Acute Normovolemic Hemodilution on Coagulation During Cardiac Surgery Using Sonorheometric Clot Analysis (Quantra QPlus): A Retrospective Pilot Study
- Open Access
- 4 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e83470
Transient Acquired von Willebrand Disease With a Type 2B Phenotype: Recognizing the Diagnostic Challenges
Acquired von Willebrand disease (vWD) may arise secondary to autoimmune conditions, hematologic malignancies, or valvular heart dysfunction. It should be included in the differential diagnosis of any acquired bleeding disorder. Most cases resemble Type 1 or Type 2A inherited vWD, typically presenting with variable decreases in von Willebrand antigen and activity. However, clinicians should exercise caution when interpreting von Willebrand panels to rule out acquired vWD, as acute phase reactants - associated with inflammation and malignancy - can artificially elevate and normalize circulating von Willebrand factor (vWF) and factor VIII levels. We present a rare case of acquired vWD with a Type 2B phenotype on platelet aggregation studies, temporally associated with diffuse large B-cell lymphoma (DLBCL). vWF and multimer assays were non-contributory, likely due to elevated acute phase reactants at the time of diagnosis, evidenced by increased factor VIII activity and falsely elevated von Willebrand antigen and activity levels. The patient's bleeding symptoms resolved following lymphoma treatment and remission. Platelet aggregation normalized, factor VIII levels returned to baseline, and von Willebrand activity stabilized. To the best of our knowledge, this case is the first to describe an association between acquired vWD with a Type 2B phenotype and DLBCL, expanding the range of hematologic malignancies linked to this rare presentation. We emphasize diagnostic challenges, particularly the role of acute-phase reactants in obscuring von Willebrand panel interpretations.
- 4 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e83470
Open AccessTransient Acquired von Willebrand Disease With a Type 2B Phenotype: Recognizing the Diagnostic Challenges
Acquired von Willebrand disease (vWD) may arise secondary to autoimmune conditions, hematologic malignancies, or valvular heart dysfunction. It should be included in the differential diagnosis of any acquired bleeding disorder. Most cases resemble Type 1 or Type 2A inherited vWD, typically presenting with variable decreases in von Willebrand antigen and activity. However, clinicians should exercise caution when interpreting von Willebrand panels to rule out acquired vWD, as acute phase reactants - associated with inflammation and malignancy - can artificially elevate and normalize circulating von Willebrand factor (vWF) and factor VIII levels. We present a rare case of acquired vWD with a Type 2B phenotype on platelet aggregation studies, temporally associated with diffuse large B-cell lymphoma (DLBCL). vWF and multimer assays were non-contributory, likely due to elevated acute phase reactants at the time of diagnosis, evidenced by increased factor VIII activity and falsely elevated von Willebrand antigen and activity levels. The patient's bleeding symptoms resolved following lymphoma treatment and remission. Platelet aggregation normalized, factor VIII levels returned to baseline, and von Willebrand activity stabilized. To the best of our knowledge, this case is the first to describe an association between acquired vWD with a Type 2B phenotype and DLBCL, expanding the range of hematologic malignancies linked to this rare presentation. We emphasize diagnostic challenges, particularly the role of acute-phase reactants in obscuring von Willebrand panel interpretations.
- 14 February 2025
- Published by Wiley in Transfusion
- Vol. 65 (2) , 420-421
Further thoughts on a lower fibrinogen threshold prior to therapeutic plasma exchange
- 14 February 2025
- Published by Wiley in Transfusion
- Vol. 65 (2) , 420-421
Further thoughts on a lower fibrinogen threshold prior to therapeutic plasma exchange